Fibroblast growth factor 23 and bone mineralisation

Area of Science:

• Endocrinology
• Nephrology
• Bone Biology

Background:

• Fibroblast growth factor 23 (FGF23) is a bone-derived hormone crucial for mineral ion homeostasis.
• Elevated FGF23 levels are observed in early chronic kidney disease (CKD), implicating it in CKD-related bone complications.
• FGF23 and its cofactor Klotho may directly regulate bone mineralization.

Purpose of the Study:

• To review the emerging role of FGF23 in bone mineralization.
• To discuss the pathophysiology of bone disorders associated with CKD.
• To highlight the independent effects of FGF23 and Klotho on bone metabolism.

Main Methods:

• Literature review of recent studies on FGF23, Klotho, and CKD.
• Analysis of findings from human genetic and animal models of mineral ion disorders.
• Synthesis of current understanding of FGF23's role in bone metabolism.

Main Results:

• FGF23 plays a critical role in maintaining mineral ion homeostasis.
• Increased FGF23 is an early marker in CKD, linked to bone and mineral disorders.
• FGF23 and Klotho may directly influence bone mineralization independent of systemic effects.

Conclusions:

• FGF23 is central to mineral ion balance and bone health.
• Understanding FGF23's role is crucial for managing CKD-related bone diseases.
• Further research into FGF23 and Klotho's direct effects on bone mineralization is warranted.